Clinical and Translational Report Inhibition of IKK 3 and TBK1 Improves Glucose Control in a Subset of Patients with Type 2 Diabetes Graphical Abstract Highlights d 12 weeks of amlexanox treatment significantly reduced HbA1c in obese, diabetic subjects d Amlexanox treatment did not affect all subjects equally d The amlexanox-treated responders had higher baseline inflammation d Energy-expenditure-associated genes were increased in responders Authors Elif A. Oral, Shannon M. Reilly, Andrew V. Gomez, ..., Michael Downes, Ronald M. Evans, Alan R. Saltiel Correspondence eliforal@med.umich.edu (E.A.O.), asaltiel@ucsd.edu (A.R.S.) In Brief Oral et al. investigate the effect of the anti- inflammatory, antiallergic drug amlexanox in a proof-of-concept clinical study of type 2 diabetes and nonalcoholic fatty liver disease. Amlexanox improved blood glucose levels in diabetic patients, and a subgroup showed enhanced response, including liver fat loss, associated with increased energy expenditure. Oral et al., 2017, Cell Metabolism 26, 157–170 July 5, 2017 ª 2017 Elsevier Inc. http://dx.doi.org/10.1016/j.cmet.2017.06.006